Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Cash & Current Investments: 2012-2024

Historic Cash & Current Investments for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Dec 2024 value amounting to $221.6 million.

  • Amphastar Pharmaceuticals' Cash & Current Investments rose 10.27% to $276.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $966.5 million, marking a year-over-year decrease of 4.74%. This contributed to the annual value of $221.6 million for FY2024, which is 13.69% down from last year.
  • As of FY2024, Amphastar Pharmaceuticals' Cash & Current Investments stood at $221.6 million, which was down 13.69% from $256.8 million recorded in FY2023.
  • In the past 5 years, Amphastar Pharmaceuticals' Cash & Current Investments registered a high of $256.8 million during FY2023, and its lowest value of $105.6 million during FY2020.
  • Moreover, its 3-year median value for Cash & Current Investments was $221.6 million (2024), whereas its average is $218.1 million.
  • As far as peak fluctuations go, Amphastar Pharmaceuticals' Cash & Current Investments surged by 46.11% in 2023, and later dropped by 13.69% in 2024.
  • Over the past 5 years, Amphastar Pharmaceuticals' Cash & Current Investments (Yearly) stood at $105.6 million in 2020, then rose by 29.40% to $136.7 million in 2021, then climbed by 28.60% to $175.8 million in 2022, then skyrocketed by 46.11% to $256.8 million in 2023, then declined by 13.69% to $221.6 million in 2024.